The Journal of Practical Medicine >

2024 , Vol. 40 >Issue 1: 43 - 47

DOI: https://doi.org/10.3969/j.issn.1006-5725.2024.01.008

Feature Reports：Lung cancer

An analysis on clinical characteristics in patients with lung adenocarcinomas tested positive for EGFR mutation in pleural effusion

  • Ying LIU ,
  • Yun LIU ,
  • Jiahui LIU ,
  • Lu WANG ,
  • Wenrui HOU ,
  • Xiaoli LI ,
  • Junxin XIANG ,
  • Dianming. LI
Expand
  • Department of Respiratory and Critical Medicine，the First Affiliated Hospital of Bengbu Medical College，Clinical Basis Diseases of Respiratory Key Laboratory of An hui Province，Bengbu 233003，China

Received date: 2023-08-11

  Online published: 2024-01-24

Fold

Abstract

Objective To analyze the clinical characteristics of lung adenocarcinoma patients with positive EGFR mutations detected in pleural effusion. Methods We retrospectively analyzed the clinical characteristics including gender， age， smoking history， presence of other underlying diseases （such as COPD， cardiovascular disease， and diabetes）， site of pleural fluid， feature of pleural fluid， and TNM stage in patients with lung adenocarcinoma who had been admitted to the first Affiliated Hospital of Bengbu Medical College from 2020.01 to 2022.12 for the first time by the detection of EGFR mutation positive in pleural effusion. The data were statistically analyzed using the SPSS 26.0 software. Results A total of 126 patients were screened for enrollment， including 61 patients （48.41%） with EGFR exon 19 deletion mutation （19del）， 56 patients （44.44%） with exon 21 L858R mutation （21L858R）， and 9 patients （7.14%） with non?classical mutations. Univariate analysis showed that the three mutation subtypes were statistically significant in terms of gender， age， smoking history， and presence of COPD （P < 0.05 for all comparisons）， but not in terms of pleural fluid site， feature of pleural fluid， tumor size， and presence of cardiovascular disease， diabetes mellitus， presence of distant metastases， and mediastinal lymph node metastases （P > 0.05 for all comparisons）； Multivariate analysis showed that 21 L858R mutation was more likely to be found in male， older age， non?smoking， and presence of COPD than 19del mutation； non?classical mutation was more likely to be found in male than 19del mutation. Conclusions There are significant differences among the three mutation subtypes in sex， age， smoking history， and presence of COPD， but not in pleural fluid location， feature of pleural fluid， tumor size， presence of cardiovascular disease or diabetes mellitus， presence of distant metastases， or mediastinal lymph node metastases； Among lung adenocarcinoma patients with positive EGFR mutations in pleural fluid， 21 L858R mutation mostly occurs in male， older age， non?smokers， and those complicated with COPD， while non?classical mutation mainly develops in male. However， more case studies are needed to confirm the above conclusions.

Key words： EGFR mutation?positive; pleural effusion; lung adenocarcinoma; clinical features

Cite this article

Ying LIU , Yun LIU , Jiahui LIU , Lu WANG , Wenrui HOU , Xiaoli LI , Junxin XIANG , Dianming. LI . An analysis on clinical characteristics in patients with lung adenocarcinomas tested positive for EGFR mutation in pleural effusion[J]. The Journal of Practical Medicine, 2024 , 40(1) : 43 -47 . DOI: 10.3969/j.issn.1006-5725.2024.01.008

References

1 刘慧敏，周乾宇，贾善群，等.2004-2018年中国肺癌死亡趋势分析及预测［J］.中国预防医学杂志，2021，22（12）：913-919.
2 THAI A A， SOLOMON B J， SEQUIST L V， et al. Lung cancer［J］. Lancet， 2021， 398（10299）：535-554.
3 GANTI A K， KLEIN A B， COTARLA I，et al. Update of incidence，prevalence，survival，and initial treatment in patients with non-small cell lung cancer in the US［J］. JAMA Oncol， 2021，7（12）：1824-1832.
4 KOEGELENBERG C F N， SHAW J A， IRUSEN E M， et al. Contemporary best practice in the management of malignant pleural effusion ［J］. Ther Adv Respir Dis， 2018，12：1-13.
5 尹文琤，张华，顾阳春， 等.76例初诊EGFR突变阳性合并胸腔积液肺腺癌患者的临床特征及预后分析：一项单中心、回顾性研究［J］.中国肺癌杂志，2022，25（3）：156-166.
6 MANSSON C T， VAD-NIELSEN J， MELDGAARD P， et al. EGFR transcription in non-small-cell lung cancer tumours can be revealed in ctDNA by cell-free chromatin immunoprecipitation （cfChIP） ［J］. Mol Oncol， 2021，15（11）：2868-2876.
7 中华医学会病理学分会细胞学组. 非小细胞肺癌恶性浆膜腔积液分子病理检测中国专家共识［J］. 中华病理学杂志， 2022，51（12）：1198-1204.
8 陆如建，褚红军，尤庆生，等. EGFR基因突变及ERCC1、RRM1表达在非小细胞肺癌精准化治疗中的应用价值［J］. 交通医学， 2017，31（2）：115-120.
9 唐珊珊，李莉，袁双虎. EGFR 19/21位点突变与597例非小细胞肺癌患者中发生脑转移的关联分析［J］. 中华肿瘤防治杂志，2019，26（10）：724-727.
10 孔君，杨雪，孔辉，等. 2394例肺腺癌患者EGFR及ALK驱动基因分析［J］. 南京医科大学学报（自然科学版），2020，40（5）：675-680，719.
11 ALIKHANYAN K， CHEN Y， KRAUT S， et al. Targeting alveolar macrophages shows better treatment response than deletion of interstitial macrophages in EGFR mutant lung adenocarcinoma［J］. Immun Inflamm Dis， 2020，8（2）：181-187.
12 CHARPIDOU A， BLATZA D， ANAGNOSTOU V，et al. EGFR mutations in non-small cell lung cancer-clinical implications［J］. In Vivo， 2008，22（4）： 529-536．
13 SHI Y， ZHOU C， HU C P，et al. A prospective，molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology （ PIONEER） ［J］. J Thocac Oncol， 2014，9（2）： 154-162．
14 ZHOU J， SONG X B， HE H，et al ． Prevalence and clinical profile of EGFR mutation in non-small cell lung carcinoma patients in southwest china［J］. Asian Pac J Cancer Prev，2016，17（3）： 965-971．
15 LIM J U， YEO C D， RHEE C K， et al. Chronic Obstructive Pulmonary Disease-Related Non-Small-Cell Lung Cancer Exhibits a Low Prevalence of EGFR and ALK Driver Mutations［J］. PLoS One， 2015，10（11）：e0142306.
16 李龙，刘海潮，胡振红，等. 慢性阻塞性肺疾病合并非小细胞肺癌患者EGFR和EML4-ALK突变特点分析［J］. 华南国防医学杂志， 2021，35（8）：549-552.
17 HOUGHTON A M， MOUDED M， SHAPIRO S D. Common origins of lung cancer and COPD［J］. Nat Med，2008，14：1023-1024.
18 王艳，张申众，袁秀敏，等. EGFR基因19或21外显子突变非小细胞肺癌的临床病理特征及靶向治疗效果［J］. 实用癌症杂志， 2019，34（5）：759-762.
19 刘仁旺，刘京豪，李昕，等. EGFR 19和21外显子突变肺癌患者的临床特征比较和预后分析［J］.中国肺癌杂志， 2014，17（11）：804-811.
20 CHEN Z， ZHANG J， HUANG K， et al. Comparison of clinicopathologic characteristics between patients with EGFR exon 19 deletion and EGFR L858R mutation in lung cancer［J］. Int J Clin Exp Pathol， 2018，11（9）：4644-4649.
21 He Y， LI S， REN S， et al. Impact of family history of cancer on the incidence of mutation in epidermal growth factor receptor gene in non-small cell lung cancer patients［J］. Lung Cancer， 2013，81：162-166.
22 ZHAO F N， ZHAO Y Q， HAN L Z，et al ．Clinicoradiological features associated with epidermal growth factor receptor exon 19 and 21 mutation in lung adenocarcinoma［J］. Clin Radiol，2018，74（1）： 80.e7-80.e17．
23 LU R L， HU C P， YANG H P，et al. Biological characteristics and epidermal growth factor receptor tyrosine kinase inhibitors efficacy of EGFR mutation and its subtypes in lung adenocarcinom ［J］. Pathol & Oncol Res， 2014，20（2）： 445-451．
24 房延凤，马李杰，刘雁声，等. 非小细胞肺癌E19-Del、L858R突变临床特征分析［J］. 中华肺部疾病杂志（电子版），2020，13（2）：164-168.
Options
Outlines

/

〈 〉